Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Saracatinib difumarate by AstraZeneca for Psychosis: Likelihood of Approval
Saracatinib difumarate is under clinical development by AstraZeneca and currently in Phase I for Psychosis. According to GlobalData, Phase I...